title: Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?
abstract: The cytocidal potency of a molecule can be augmented by conjugating a radionuclide for molecular targeted radionuclide therapy (MTRT) for cancer. Radioimmunotherapy (RIT) should be incorporated into the management of patients with B-cell non-Hodgkin's lymphoma (NHL) soon after the patients have proven incurable. Better drugs, strategies, and combinations with other drugs seem certain to make RIT integral to the management of patients with NHL and likely to lead to a cure of the currently incurable NHL. These improved drugs, strategies, and combinations thereof also offer opportunities for RIT to become part of the management of solid malignancies, including epithelial cancers. Smaller radionuclide carriers, such as those used for pretargeted strategies, provide dose intensification. The potential of pretargeted RIT to improve patient outcomes is striking.
authors.affiliation: Department of Internal Medicine, University of California, Davis, Sacramento, CA 95816, USA. gldenardo@ucdavis.edu
authors.forename: Gerald L
authors.initials: GL
authors.lastname: DeNardo
authors.forename: Sally J
authors.initials: SJ
authors.lastname: DeNardo
authors.forename: Rod
authors.initials: R
authors.lastname: Balhorn
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy / Q000379:methods; D004307:Dose-Response Relationship, Radiation; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008223:Lymphoma / Q000532:radiotherapy* / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000532:radiotherapy / Q000628:therapy; D009369:Neoplasms / Q000532:radiotherapy* / Q000628:therapy; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D016499:Radioimmunotherapy / Q000009:adverse effects / Q000379:methods; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods*; D011879:Radiotherapy Dosage; D016879:Salvage Therapy / Q000379:methods
chemical_list: D011838:Radiation-Sensitizing Agents
references.citation: Cancer Biother Radiopharm. 1998 Aug;13(4):239-54
references.pmid: 10850360
references.citation: Clin Cancer Res. 1997 Sep;3(9):1547-55
references.pmid: 9815842
references.citation: Cancer Biother Radiopharm. 2001 Aug;16(4):305-15
references.pmid: 11603001
references.citation: Clin Cancer Res. 2004 Dec 1;10(23):7792-8
references.pmid: 15585610
references.citation: Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
references.pmid: 2032882
references.citation: J Nucl Med. 2007 Aug;48(8):1357-68
references.pmid: 17631548
references.citation: J Nucl Med. 1997 Aug;38(8):1180-5
references.pmid: 9255145
references.citation: J Nucl Med. 2005 Jan;46 Suppl 1:67S-75S
references.pmid: 15653654
references.citation: Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3712-21
references.pmid: 14506163
references.citation: Clin Cancer Res. 2001 Jan;7(1):175-84
references.pmid: 11205906
references.citation: Blood. 2002 Jun 15;99(12):4336-42
references.pmid: 12036859
references.citation: J Clin Oncol. 2004 Sep 1;22(17):3593-607
references.pmid: 15337810
references.citation: J Nucl Med. 2003 Mar;44(3):400-11
references.pmid: 12621007
references.citation: Cancer Biother Radiopharm. 2007 Aug;22(4):453-68
references.pmid: 17803440
references.citation: Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1802-7
references.pmid: 10677537
references.citation: Cancer Biother Radiopharm. 2008 Dec;23(6):783-96
references.pmid: 20443696
references.citation: Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S46-56
references.pmid: 16979440
references.citation: Blood. 2004 Jun 15;103(12):4429-31
references.pmid: 15016644
references.citation: J Nucl Med. 2003 Mar;44(3):465-74
references.pmid: 12621016
references.citation: J Clin Oncol. 1998 Oct;16(10):3246-56
references.pmid: 9779698
references.citation: Methods Mol Biol. 2004;248:209-25
references.pmid: 14970499
references.citation: Blood. 2006 Jul 1;108(1):328-36
references.pmid: 16556891
references.citation: J Endocrinol Invest. 2005;28(11 Suppl International):146-50
references.pmid: 16625865
references.citation: Cancer Res. 1995 Dec 1;55(23 Suppl):5921s-5924s
references.pmid: 7493371
references.citation: Cancer. 1994 Feb 1;73(3 Suppl):1023-32
references.pmid: 8306244
references.citation: J Clin Oncol. 1998 Oct;16(10):3270-8
references.pmid: 9779701
references.citation: J Clin Oncol. 2001 Oct 1;19(19):3918-28
references.pmid: 11579112
references.citation: Curr Probl Cancer. 2002 May-Jun;26(3):109-64
references.pmid: 12085086
references.citation: Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4000-4
references.pmid: 9108094
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7565-73
references.pmid: 16186600
references.citation: N Engl J Med. 2005 Feb 3;352(5):441-9
references.pmid: 15689582
references.citation: J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S
references.pmid: 15653647
references.citation: Bioconjug Chem. 2007 May-Jun;18(3):912-21
references.pmid: 17373772
references.citation: Blood. 2002 May 1;99(9):3158-62
references.pmid: 11964278
references.citation: J Nucl Med. 1992 Sep;33(9):1648-53
references.pmid: 1517839
references.citation: Cancer Biother Radiopharm. 2007 Oct;22(5):573-84
references.pmid: 17979560
references.citation: Lancet. 1995 Aug 5;346(8971):336-40
references.pmid: 7623531
references.citation: Proc Natl Acad Sci U S A. 2006 May 2;103(18):6841-6
references.pmid: 16636283
references.citation: Blood. 2003 Oct 1;102(7):2351-7
references.pmid: 12750161
references.citation: Cancer. 1997 Dec 15;80(12 Suppl):2583-90
references.pmid: 9406713
references.citation: Int J Oncol. 2007 Oct;31(4):729-40
references.pmid: 17786303
references.citation: Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5621s-5628s
references.pmid: 17875798
references.citation: Semin Oncol. 2005 Feb;32(1 Suppl 1):S27-35
references.pmid: 15786023
references.citation: Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7075s-7079s
references.pmid: 16203805
references.citation: J Natl Cancer Inst. 1990 May 2;82(9):763-71
references.pmid: 2182892
references.citation: Blood. 2000 Nov 1;96(9):2934-42
references.pmid: 11049969
references.citation: Blood. 2008 Feb 15;111(4):2261-8
references.pmid: 18042793
references.citation: Blood. 2001 Oct 15;98(8):2535-43
references.pmid: 11588052
references.citation: Semin Nucl Med. 2006 Apr;36(2):147-56
references.pmid: 16517236
references.citation: J Nucl Med. 2006 Aug;47(8):1238-40
references.pmid: 16882999
references.citation: J Clin Oncol. 2002 May 15;20(10):2453-63
references.pmid: 12011122
references.citation: Endocr Relat Cancer. 2004 Dec;11(4):689-708
references.pmid: 15613446
references.citation: Blood. 2003 Sep 1;102(5):1606-12
references.pmid: 12738671
references.citation: Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232
references.pmid: 7612182
references.citation: Cancer Biother Radiopharm. 2005 Apr;20(2):185-8
references.pmid: 15869453
references.citation: Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7109s-7121s
references.pmid: 16203810
references.citation: Mol Imaging Biol. 2009 Jan-Feb;11(1):39-45
references.pmid: 18773247
references.citation: Update Cancer Ther. 2007 Mar;2(1):19-31
references.pmid: 18311322
references.citation: J Clin Oncol. 2002 Aug 1;20(15):3262-9
references.pmid: 12149300
references.citation: J Nucl Med. 2008 Jan;49(1):158-63
references.pmid: 18077530
references.citation: J Radiat Res. 2005 Jun;46(2):241-8
references.pmid: 15988143
references.citation: Cancer. 2002 Feb 15;94(4 Suppl):1332-48
references.pmid: 11877764
references.citation: J Clin Oncol. 2005 Sep 20;23(27):6763-70
references.pmid: 16170184
references.citation: Eur J Nucl Med. 1999 Feb;26(2):110-20
references.pmid: 9933344
references.citation: Clin Cancer Res. 1999 Oct;5(10 Suppl):3243s-3248s
references.pmid: 10541370
references.citation: J Nucl Med. 2005 Jan;46 Suppl 1:128S-40S
references.pmid: 15653661
references.citation: Clin Lymphoma. 2000 Jun;1(1):46-54
references.pmid: 11707813
references.citation: Blood. 2004 Jul 1;104(1):227-36
references.pmid: 14996706
references.citation: Blood. 2000 Aug 15;96(4):1259-66
references.pmid: 10942366
references.citation: Cancer Biother Radiopharm. 2000 Feb;15(1):15-29
references.pmid: 10740649
references.citation: J Nucl Med. 2008 Apr;49(4):674-8
references.pmid: 18344431
references.citation: J Immunol. 1985 Dec;135(6):3795-801
references.pmid: 2415587
references.citation: Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):478-85
references.pmid: 15655678
references.citation: Blood. 2003 Mar 15;101(6):2340-8
references.pmid: 12446461
references.citation: Cancer Biother Radiopharm. 2006 Dec;21(6):645-54
references.pmid: 17257080
references.citation: J Clin Oncol. 2006 Feb 10;24(5):823-34
references.pmid: 16380412
references.citation: J Clin Oncol. 2006 Apr 10;24(11):1705-11
references.pmid: 16549819
references.citation: Clin Cancer Res. 1999 Oct;5(10 Suppl):3224s-3231s
references.pmid: 10541368
references.citation: J Nucl Med. 2001 Feb;42(2):213-21
references.pmid: 11216519